|9 Months Ended|
Sep. 30, 2022
|NOTE 4 - INTANGIBLE ASSET||
NOTE 4 – INTANGIBLE ASSET
The Company has capitalized the costs associated with acquiring the exclusive worldwide license to develop and commercialize products comprising or containing the proprietary therapeutic compound ART27.13, formerly known as NEO1940 as an intangible asset at a value of $2,039 as of September 30, 2022, and December 31, 2021.
The amount capitalized consisted of a $1,500 payment and the fair value of 4,087 shares of Common Stock of $539. During the nine months ended September 30, 2022, no additional costs met the criteria for capitalization as an intangible asset.
The entire disclosure for all or part of the information related to intangible assets.
Reference 1: http://www.xbrl.org/2003/role/disclosureRef